Ovarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread

dc.contributor.authorGendrau-Sanclemente, Núria
dc.contributor.authorFigueras i Amat, Agnès
dc.contributor.authorGracova, Kristina
dc.contributor.authorLahiguera, Álvaro
dc.contributor.authorAlsina Sanchís, Elisenda
dc.contributor.authorMarín Jiménez, Juan A.
dc.contributor.authorVidal-Bel, August
dc.contributor.authorMatias-Guiu, Xavier, 1958-
dc.contributor.authorFernández González, Sergi
dc.contributor.authorBarahona, Marc
dc.contributor.authorMartí, Lola
dc.contributor.authorPonce i Sebastià, Jordi
dc.contributor.authorViñals Canals, Francesc
dc.date.accessioned2025-06-27T18:22:23Z
dc.date.available2025-06-27T18:22:23Z
dc.date.issued2023-11-27
dc.date.updated2025-06-27T18:22:23Z
dc.description.abstractHigh-grade serous ovarian cancer (HGSOC) is the deadliest gynecological malignancy. The most common form of metastatic spread of HGSOC is transcoelomic dissemination. In this process, detached cells from the primary tumor aggregate as tumorspheres and promote the accumulation of peritoneal ascites. This represents an early event in HGSOC development and is indicative of poor prognosis. In this study, based on tumorspheres isolated from ascitic liquid samples from HGSOC patients, ovarian cancer spheroid 3D cultures, and in vivo models, we describe a key signal for tumorsphere formation in HGSOC. We report that platelet-derived growth factor receptor beta (PDGFRβ) is essential for fibronectin-mediated cell clustering of ovarian cancer cells into tumorspheres. This effect is mediated by the kinase NUAK family SNF1-like kinase 1 (NUAK1) and blocked by PDGFRβ pharmacological or genetic inhibition. In the absence of PDGFRβ, ovarian cancer cells can be provided with fibronectin by cancer-associated fibroblasts to generate chimeric spheroids. This work provides new insights that uncover potential targets to prevent peritoneal dissemination, the main cause of advanced disease in HGSOC patients.
dc.format.extent20 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec740875
dc.identifier.issn1574-7891
dc.identifier.pmid38010623
dc.identifier.urihttps://hdl.handle.net/2445/221876
dc.language.isoeng
dc.publisherElsevier
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1002/1878-0261.13556
dc.relation.ispartofMolecular Oncology, 2023, vol. 18, num.1, p. 136-155
dc.relation.urihttps://doi.org/10.1002/1878-0261.13556
dc.rightscc-by (c) Gendrau-Sanclemente, N. et al., 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationAscites
dc.subject.classificationCàncer d'ovari
dc.subject.classificationFibroblasts
dc.subject.otherAscites
dc.subject.otherOvarian cancer
dc.subject.otherFibroblasts
dc.titleOvarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
836841.pdf
Mida:
12.04 MB
Format:
Adobe Portable Document Format

Paquet de llicències

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
license.txt
Mida:
1.71 KB
Format:
Item-specific license agreed upon to submission
Descripció: